A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
Study of Lenalidomide in Combination with Chemotherapy in Patients with HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)
Sponsor: NIH
Enrolling: Male and Female Patients
IRB Number: AAAT9880
U.S. Govt. ID: NCT04301076
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the safety and tolerability (side effects) of adding a study drug called lenalidomide at different doses in combination with the usual treatment with EPOCH chemotherapy. Dose is defined as the amount of drug a patient gets, such as 15 mg. These drugs have already been approved by the FDA for other types of cancer. This study tests different doses of the lenalidomide to see which dose is safer and more tolerable for people when combined with EPOCH chemotherapy. Another purpose of the study is genetic testing using tumor tissue to see if the combination of drugs may work in treating specific types of cancer. In addition, another objective of the study is to see how the combination of drugs affects HTLV levels and the number of immune cells in patients' blood. This is the first time all of these drugs will be tested together in patients with HTLV-associated adult T-cell leukemia-lymphoma (ATLL). There will be about 30 people taking part in this study.
Jennifer Amengual, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)? Yes No
Are you able to make regularly scheduled visits to the clinic for treatment and examinations? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator